Introduction {#sec1}
============

Chronic kidney disease (CKD) is one of the major noncommunicable diseases worldwide, especially in the aging population ([@bib1], [@bib2]). A deceptive feature of renal failure, it can remain unnoticed by patients until the disease progresses, making CKD one of the most challenging diseases to diagnose, and is considered a silent killer ([@bib3]). Progression of CKD has been thought to be initiated by renal injury, followed by a defective repair process that subsequently causes impaired nephron function and compensatory response of the remaining nephrons to maintain renal function ([@bib4]). However, a vicious cycle of these alterations continues, resulting in mechanical and metabolic stresses and ultimately loss of the nephron ([@bib4]). Because of the increasing expenditure on CKD, much greater efforts have been made during the last decade toward its prevention ([@bib5]).

Epigallocatechin-3-gallate (EGCG) is the most abundant catechin derived from the tea plant (*Camelliasinensis*), especially green tea, which contains ∼77.8 mg EGCG per gram of dried leaves (accounting for 60% of all catechins found in tea polyphenols) ([@bib6]). Computational molecular docking and X-ray crystallographic studies have revealed that EGCG can anchor a galloyl moiety in a protein cleft and interact with the protein through its hydroxyl groups, giving it greater biological activity than nongalloylated catechins ([@bib7]). EGCG is widely recognized as a potent antioxidant that effectively eliminates intracellular free radicals by its phenol ring structure, which can act as an electron trap ([@bib8]). In addition, anti-inflammatory, antiaging, and

antifibrosis properties of EGCG appear to involve several molecular signaling pathways and cellular machineries that are responsible for specified cellular functions under physiological and pathological conditions ([@bib9], [@bib10]). Therefore, EGCG has received wide attention for its beneficial roles in chronic diseases (e.g., cardiovascular and neurodegenerative diseases and various types of cancers), which frequently involve sustained oxidative stress and inflammation ([@bib11]). Recently, several lines of evidence from various in vitro and in vivo animal studies have suggested that EGCG exerts renoprotection against CKD ([@bib12], [@bib13]). This review summarizes the current knowledge and recent progress made in this research area. Also discussed are future perspectives, challenges, and concerns over the clinical use of EGCG for CKD and renal fibrosis.

Preclinical Evidence for Molecular Mechanisms of EGCG in CKD and Renal Fibrosis {#sec2}
===============================================================================

Antioxidant property of EGCG {#sec2-1}
----------------------------

### Preservation of mitochondrial function {#sec2-1-1}

Mitochondria play several important roles in cellular adaptive responses to a stressful environment. In general, mitochondria are important for biosynthesis of macromolecules, regulation of calcium homeostasis, maintenance of cellular redox status, and regulation of apoptotic cell death ([@bib14]). In addition to the heart, the kidney is another mitochondria-rich organ per tissue mass ([@bib15]). Therefore, renal functions are highly dependent on mitochondrial performance to maintain body homeostasis ([@bib16]). Moreover, the kidney is highly sensitive to cellular redox imbalance, resulting in overproduction of reactive oxygen species (ROS) and subsequently oxidative stress, which is critical for development of several kidney diseases ([@bib17], [@bib18]).

It has been hypothesized that mitochondrial dysfunction contributes to the progression of CKD, particularly in diabetic nephropathy (DN) ([@bib17], [@bib19]). Renoprotective effects of EGCG against mitochondrial dysfunction have been extensively studied in CKD. In rats with DN induced by streptozotocin injection and nephrectomy, oral administration of EGCG for 50 d suppressed hyperglycemia and proteinuria ([@bib20]). Decreases in lipid peroxidation and advanced glycation end products (AGEs) were observed, indicating an improvement in mitochondrial oxidative stress ([@bib20]). An in vitro study using human embryonic kidney (HEK) cells treated with high glucose concentration revealed that EGCG in combination with lipoic acid attenuated suppression of superoxide dismutase expression and ROS overproduction caused by high glucose ([@bib21]). Regarding the role of mitochondria in regulating apoptotic cell death, a recent study has revealed antiapoptotic activity of EGCG in DN rats ([@bib22]). Supplementation with EGCG suppressed expression of the apoptotic protein Bax and active caspase 3, but maintained expression of the antiapoptotic protein B cell lymphoma-2 (Bcl-2) in the diabetic kidney ([@bib22]). Similar findings were observed in models of renal ischemia-reperfusion injury in rats ([@bib23]) and unilateral ureteral obstruction (UUO) in mice ([@bib24]).

Cisplatin has been used for chemotherapy in many solid tumors but can induce toxic renal effects. It is thus worth mentioning a protective role of EGCG against mitochondrial oxidative stress and dysfunction in cisplatin-induced nephrotoxicity ([@bib25]). Patients who survive acute kidney injury (AKI) can have a 2-fold greater risk of developing CKD in their lifetime ([@bib26]). In a mouse model of cisplatin-induced nephrotoxicity, EGCG preserved renal mitochondrial function by maintaining electron transport and mitochondrial antioxidant enzyme activities, leading to protection against inflammation and apoptotic cell death ([@bib27]). In addition, EGCG reduced mitochondrial ROS production in HK-2 cells ([@bib27]). Consistent with the previous study, combined treatment of EGCG and coenzyme Q10 in a rat model of cisplatin-induced renal damage attenuated oxidative stress, inflammation, and renal cell death ([@bib28]). Additionally, EGCG attenuated cisplatin-induced nephrotoxicity in animals with solid Ehrlich ascites carcinoma by increasing concentration of the antioxidant glutathione ([@bib10]). Likewise, EGCG protected renal cells against cisplatin-induced apoptosis by inhibiting Bax, while promoting Bcl-2 expression ([@bib29]). Moreover, beneficial effects of EGCG on aging and kidney function have been also reported ([@bib30]). Supplementation of EGCG for 6 mo in Fischer 344 rats reduced oxidative damage (by lowering H~2~O~2~ and malondialdehyde), increased mitochondrial membrane potential of lymphocytes, and increased antioxidant enzyme activities ([@bib30]).

### Activation of Nrf2/HO-1 signaling {#sec2-1-2}

Kelch-like ECH-associated protein 1 (Keap1) coordinates with nuclear factor erythroid 2-related factor 2 (Nrf2) to govern the defense mechanism against oxidative and electrophilic stresses ([@bib31]). Under quiescent conditions, Keap1 quenches Nrf2 activity by forming an E3 ubiquitin ligase complex with cullin-3 (Cul3) that links Nrf2 with E2 ubiquitin-conjugating enzyme, which transfers ubiquitin to Nrf2 and targets Nrf2 for proteasomal degradation ([@bib32]). However, exposure to an electrophile can directly modify the reactive cysteine residues inside Keap1, and consequently reduce the E3 ubiquitin ligase activity of the Keap1-Cul3 complex and release Nrf2 from E2 ubiquitin-conjugating enzyme ([@bib33]). Nascent Nrf2 then translocates to the nucleus, where it combines with small musculoaponeurotic fibrosarcoma (sMAF) protein, and subsequently binds to the antioxidant response elements of a myriad cytoprotective genes and activates their transcripts ([@bib34]). Prolonged activation of Nrf2 can exert the dark side of Nrf2 in cancer progression and chemoresistance ([@bib35], [@bib36]). However, this is not the case for CKD, in which pharmacological activation of Nrf2 is nowadays considered as one of the strategies to reduce oxidative stress and to prevent the disease progression ([@bib37]).

EGCG has been documented as a phytochemical that can modulate Nrf2 signaling, resulting in upregulation of antioxidant or detoxifying enzymes ([@bib38]). In the context of CKD, antioxidative activity of EGCG has been evaluated in lupus nephritis (LN) ([@bib39]). In such a study, daily supplementation of EGCG in a mouse model of LN improved renal function and prevented proteinuria. In addition, oxidative stress parameters in serum, urine, and kidney were significantly lowered in the EGCG-treated mice. Moreover, nuclear translocation of Nrf2 was observed in the EGCG-treated mice in concordance with the increased expression or activities of its downstream phase II enzymes \[i.e., NAD(P)H:quinone oxidoreductase, heme oxygenase-1 (HO-1) and glutathione peroxidase (GPx)\]), indicating Nrf2 activation by electrophilic EGCG ([@bib39]).

Similarly, the therapeutic potential of EGCG has been shown in a mouse model of crescentic glomerulonephritis (GN) ([@bib40]). In this study, EGCG-treated mice showed improved renal function and histopathology. EGCG treatment also restored expression of nuclear Nrf2 and its downstream targets, including glutamate--cysteine ligase catalytic subunit, glutamate--cysteine ligase modifier subunit, and GPx ([@bib40]). In addition, the renal glutathione expression level was increased whereas the renal malondialdehyde expression level was decreased in the EGCG-treated mice, suggesting a reduction of oxidative stress by Nrf2 restoration ([@bib40]). These findings imply that EGCG could reactivate the Nrf2 pathway, thereby reversing the progression of crescentic GN.

In a mouse model of high-fat-diet--induced obesity, the EGCG-treated animals showed significant reduction in fasting blood glucose and AGE formation, most likely via Nrf2 activation as shown by the increased expression levels of nuclear Nrf2 and HO-1 ([@bib41]). Interestingly, EGCG prevented DN in streptozotocin-induced diabetic mice via Nrf2 activation ([@bib42]). *Nrf2*-knockout mice showed a complete abolition of such protective effects of ECGC against DN, resulting in sustained oxidative stress, inflammation, and fibrosis ([@bib42]). In addition, direct evidence by molecular docking assay revealed that EGCG directly interacted with the Keap1 interior by hydrogen bonding ([@bib42]). This direct interaction of EGCG with Keap1 was confirmed by a silencing assay using small interfering RNA (siRNA) specific to Keap1 ([@bib42]).

Activation of Nrf2 by EGCG has been also reported in a UUO model of obstructive nephropathy ([@bib43], [@bib44]). Intraperitoneal injection of EGCG after unilateral ureteral ligation improved renal ultrastructure, especially in renal tubules ([@bib43]). The amelioration of the renal injury was inferred from the increased expression of Nrf2 and its nuclear translocation as well as the increased expression of γ-glutamylcysteine synthetase (γ-GCS) in the kidney ([@bib43]). Similarly, another study demonstrated that 14-d administration of EGCG in UUO mice ameliorated renal damage and renal dysfunction through activation of Nrf2 as shown by the increase in Nrf2 and its nuclear accumulation, resulting in enhanced HO-1 production ([@bib44]). Moreover, a recent in vitro study has also shown that EGCG protects renal cells from oxidative damage induced by H~2~O~2~ through Nrf2 activation, resulting in increased γ-GCS expression ([@bib45]).

Anti-inflammatory activity of EGCG {#sec2-2}
----------------------------------

Uncontrolled inflammation is an intermediate mechanism in the development of many chronic diseases including CKD. The NF-κB pathway is recognized as a classical pathway regulating expression of proinflammatory cytokines/chemokines in response to inflammation ([@bib46]). Both canonical and noncanonical NF-κB pathways have been discovered in various inflammatory kidney diseases ([@bib47], [@bib48]). However, the most common form of activated NF-κB stimulated by a pathological condition is the heterodimeric complex of p65/p50 ([@bib46]). During the resting state, heterodimeric p65/p50 is kept inactive by the IκΒ inhibitory protein. Shortly after stimulation, inhibitor of kappa B (IκB) is phosphorylated by the NF-κB essential modulator (NEMO)-containing IκB kinase complex and is marked for degradation via proteasomes, resulting in nuclear translocation of p65/p50 and binding of the complex to promoter regions of genes encoding proinflammatory mediators ([@bib49], [@bib50]). Therefore, targeting the NF-κB signaling pathway in order to alleviate the inflammatory response and to restore a proper balance of anti-inflammatory signaling pathways is a strategic approach in the context of chronic diseases ([@bib51]).

The anti-inflammatory property of EGCG has been reported in many models of CKD, including DN, immune-mediated kidney diseases, and renal fibrosis. In general, EGCG exhibits anti-inflammatory effects by inhibiting the NF-κB pathway, resulting in reduction of proinflammatory mediators and decreased recruitment of inflammatory cells. An in vitro study of AGE-induced inflammation of HEK cells and human mesangial cells revealed that both of these renal cells had significantly increased concentration of the proinflammatory cytokine TNF-α upon AGE treatment, but pretreatment with EGCG could attenuate such an increase ([@bib52]). Interestingly, the inhibitory property of EGCG was comparable to that of L-165,041, a selective ligand for peroxisome proliferator-activated receptor delta (PPARδ) ([@bib52]). In addition, both EGCG and L-165,041 induced PPARδ while suppressing expression of receptor of AGE (RAGE). Accordingly, EGCG suppressed activation of NF-κB as indicated by the decreased expression of nuclear NF-κB and the remaining IκB in the cytoplasm ([@bib52]). However, this effect was abolished by siRNA specific to PPARδ. These findings indicate that the inhibitory effect of EGCG on AGE-induced inflammation is mediated through PPARδ activation ([@bib52]). Similarly, EGCG in combination with alpha-lipoic acid had an anti-inflammatory effect on high glucose-treated HEK cells by reducing the production of proinflammatory cytokines (i.e., TNF-α and IL-6) and RAGE expression ([@bib21]).

The anti-inflammatory action of EGCG has been also demonstrated in vivo using a rat model of streptozotocin-induced DN ([@bib20]). EGCG treatment significantly inhibited NF-κB signaling, resulting in decreased expression levels of NF-κB and p-IκB-α as well as downstream enzymes, namely, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 ([@bib20]). EGCG treatment also ameliorated renal pathological changes (including mesangial matrix expansion and glomerular enlargement) and markedly reduced expression of inflammatory markers, including intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in the diabetic mice ([@bib42]). However, such protective effects of EGCG were not found in the *Nrf2*-knockout diabetic mice, suggesting that the anti-inflammatory effects of EGCG were mediated through Nrf2 signaling ([@bib42]).

Furthermore, the anti-inflammatory effects of EGCG have been demonstrated in immune-mediated CKD, including GN and LN. EGCG inhibited inflammation induced by anti--glomerular basement membrane antibody in 129/svJ GN mice ([@bib53]). Histopathology showed improvement of glomerular and tubulointerstitial injury and significant reduction of macrophage and lymphocyte infiltration together with downregulation of osteopontin, a known marker for monocyte/macrophage recruitment, in the EGCG-treated mice ([@bib53]). Additionally, p65/NF-κB molecules were stained strongly positive in the GN renal tissues, indicating NF-κB activation in GN. EGCG pretreatment ameliorated such NF-κB activation markers and also reduced iNOS expression ([@bib53]). The same group of investigators later demonstrated that the inhibitory activity of EGCG against inflammation observed in crescentic GN was Nrf2-dependent ([@bib40]). Another study in mesangial cells isolated from the kidney of mice with GN induced by systemic lupus erythematosus--like disease demonstrated that EGCG suppressed nuclear translocation of NF-κB induced by LPS and IFN-γ, resulting in downregulation of iNOS and proinflammatory mediators ([@bib54]). Likewise, a reduction of renal expression of p65/NF-κB has been found in EGCG-treated LN mice ([@bib39]). This was consistent with the decreased number of infiltrating immune cells (i.e., T-cells and macrophages). In addition, EGCG markedly reduced expression of nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3 (NLRP3) and production of IL-1β and IL-18. This effect was confirmed by decreased expression of mature caspase-1 (p20 subunit), suggesting an inhibitory effect of EGCG on NLRP3-dependent inflammasome activation ([@bib39]).

In an obstructive nephropathy model, EGCG inhibited NF-κB signaling as shown by significantly decreased expression levels of NF-κB and p-IκB, which were related to a decrease in DNA binding activity of NF-κB determined by electrophoretic mobility shift assay ([@bib44]). The decreased expression levels of proinflammatory cytokines (i.e., TNF-α, IL-6, and IL-1β) were also observed in the EGCG-treated group ([@bib44]). In addition, the same group of investigators demonstrated by histological staining of renal sections that EGCG inhibited infiltrating macrophages ([@bib55]).

Besides CKD, a beneficial effect of EGCG on age-associated kidney inflammation has been demonstrated in healthy rats ([@bib56]). Long-term consumption of EGCG decreased renal expression of NF-κB and proinflammatory mediators IL-6 and TNF-α in Wistar rats. Interestingly, these findings were correlated with the increase in longevity factors, sirtuin (SIRT1) and forkhead box O3 (FOXO3a), in liver and kidney as well as the extended lifespan of EGCG-treated rats. These data suggest that the anti-inflammatory activity of EGCG might be mediated by increasing SIRT1 and FOXO3a expression ([@bib56]).

EGCG and other signaling pathways {#sec2-3}
---------------------------------

Apart from the 2 major signaling pathways (Nrf2 and NF-κB pathways), EGCG can also regulate other signaling pathways. Pharmacological inhibition of PPAR-γ (an anti-inflammatory transcription factor) by using GW9662 diminished the renoprotective effect of EGCG ([@bib53]). This finding was concomitant with an inability of EGCG to mitigate activation of Akt and extracellular signal-regulated kinases 1 and 2 (ERK1/2), suggesting that the anti-inflammatory property of EGCG in GN could be mediated at least through PPAR-γ, Akt, and mitogen-activated protein kinase (MAPK) pathways ([@bib53]). EGCG also inhibited inflammation induced by both NF-κB activation and the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway in a mouse model of GN ([@bib54]). In this regard, EGCG blocked the PI3K/Akt/mTOR pathway as indicated by decreasing phospho-Akt and phospho-p70s6K ([@bib54]). These results were further confirmed by another study providing evidence that the anti-inflammatory activity of EGCG in a model of GN was mediated by inhibiting multiple signaling pathways, including PI3K, Akt, and MAPK pathways \[i.e., c-Jun N-terminal kinase (JNK), ERK1/2, and p38\] ([@bib40]).

Additionally, an antiapoptotic effect of EGCG has been demonstrated in UUO mice ([@bib24]). Decreased expression levels of Bax, active caspase 3, and poly ADP-ribose polymerase were observed in the EGCG-treated mice, indicating inhibition of the apoptotic pathway ([@bib24]). EGCG also inhibited activation of the MAPK pathway observed in the obstructed kidney as shown by decreasing phosphorylation of ERK, JNK, and p38 ([@bib24]). In concordance, this inhibitory effect was confirmed in the TGF-β1--treated NRK-52E cell line ([@bib24]). Taken together, the data suggest that EGCG can inhibit apoptosis of renal tubular cells in UUO mice by inactivation of the TGF-β1--induced MAPK pathway ([@bib24]).

Anti--epithelial mesenchymal transition property of EGCG {#sec2-4}
--------------------------------------------------------

Epithelial mesenchymal transition (EMT) is a process that normally occurs during embryogenesis, allowing phenotypic change of epithelial cells to acquire mesenchymal features to perform specific organ functions ([@bib57]). However, EMT can occur under pathological conditions, for example, cancer metastasis and organ fibrogenesis ([@bib57], [@bib58]). The fibrogenic milieu is primed by sustained renal injury followed by an inflammatory response and activation/expansion of fibrogenic effector cells, for example, extracellular matrix (ECM)--producing cells ([@bib59], [@bib60]). These ECM-producing cells are of mesenchymal origin, including fibroblasts, myofibroblasts, fibrocytes, pericytes, and cells derived from transdifferentiation of tubular epithelial cells through EMT ([@bib61]). Fibrotic mediators such as TGF-β1 are well documented to induce epithelial cells to undergo EMT, in which they lose their epithelial phenotypes \[markers include E-cadherin, zonula occludens-1 (ZO-1), and cytokeratins\] while gaining mesenchymal phenotypes \[markers include α-smooth muscle actin (α-SMA) and vimentin\] and contributing to ECM production ([@bib62], [@bib63]). Although a recent study has elucidated that EMT-derived myofibroblasts contributed only 5% to ECM production in renal fibrosis, it is imperative to prevent or inhibit such pathological cellular events ([@bib61]).

The protective effect of EGCG against EMT has been reported in TGF-β1--treated renal tubular epithelial cells ([@bib64]). EGCG reduced mesenchymal-like features of the TGF-β1--treated cells by restoring cytokeratin-18 and α-SMA expression. In addition, EGCG suppressed activation of Smad3, ERK1/2, and β-catenin, suggesting that its anti-EMT might be mediated through these signaling molecules ([@bib64]). In the UUO mouse model ([@bib55], [@bib65]), EGCG alleviated renal injury and renal interstitial fibrosis ([@bib55]). These findings were accompanied by a reduction of collagen production and α-SMA expression, and increase in expression of E-cadherin ([@bib55]). An in vitro study showed that EGCG inhibited TGF-β1--induced Smad2/3 phosphorylation, and promoted Nrf2 expression and its nuclear accumulation in renal tubular cells ([@bib65]). A similar effect was observed when Nrf2 was overexpressed. By contrast, Nrf2 knockdown abolished these beneficial effects of EGCG, as indicated by the increased expression of fibrotic proteins such as collagen and α-SMA ([@bib65]). Collectively, these findings indicated that the anti-EMT property of EGCG against TGF-β1/Smad signaling was mediated through the Nrf2 pathway ([@bib65]).

The antifibrotic effect of EGCG has been also investigated in another model of EMT induced by high concentration of oxalate ([@bib66]). Pretreatment with EGCG suppressed expression of EMT markers (vimentin and fibronectin) whereas it maintained epithelial markers (E-cadherin, occludin, cytokeratin, and ZO-1) in the oxalate-treated renal tubular cells. In addition, EGCG significantly reduced oxalate-induced ROS overproduction and enhanced expression of an antioxidant catalase enzyme ([@bib66]). Moreover, these beneficial effects of EGCG were abrogated by Nrf2 silencing, indicating that the protective mechanism of EGCG against oxalate-induced EMT was most likely due to its antioxidative property to reduce ROS overproduction through Nrf2 activation ([@bib66]). In addition, EGCG exhibited its anti-EMT property in a rat model of cadmium-induced chronic renal injury and fibrosis ([@bib67]). Supplementation with EGCG attenuated the increased expression levels of TGF-β1, p-Smad3, α-SMA, and vimentin. Interestingly, EGCG affected expression of several microRNAs regulated by TGF-β1/Smad signaling \[TGF-β1--induced miR-21 and miR-192 were suppressed, whereas the antifibrotic miR-29 family (miR29a/b/c) was enhanced\] ([@bib67]).

Summary of Preclinical Evidence {#sec3}
===============================

Molecular targets of EGCG are mostly proteins that can be classified as membrane receptors, transcription factors, epigenetic regulators, inflammatory molecules, intracellular enzymes, cell cycle--related proteins, apoptosis-related proteins, and others ([@bib68]). Studies of molecular interactions of EGCG and proteins have revealed that EGCG modifies enzymatic activities and bioactivities of other proteins by occupying protein active sites ([@bib69]). In addition, dynamic interactions between EGCG and proteins can affect many biological processes through regulation of transcription, posttranslational modifications, and epigenetic changes, which largely depend on cell types ([@bib70]). In the context of CKD, previous and recent preclinical studies have indicated that EGCG could prevent CKD by several mechanisms, including preservation of mitochondrial function, activation of Nrf2/HO-1 signaling, anti-inflammation, and prevention of EMT (see the summary in [**Figure 1**](#fig1){ref-type="fig"}). Continuing efforts are underway to prevent and mitigate progression of CKD. Although the precise mechanisms of the disease progression remain to be clarified, aberrant oxidative stress and inflammation are recognized as the crucial players contributing to the renal damage in CKD ([@bib73]). Therefore, maintaining redox balance in the kidney would provide a key strategy for defining new therapeutic interventions. Based on the molecular mechanisms of EGCG and its renoprotective effects, it might be possible to develop EGCG or its derivatives for treatment of CKD in 2 ways: *1*) as an Nrf2 activator, and *2*) as a mitochondria-targeting agent.

![Summary of molecular basis on which epigallocatechin-3-gallate (EGCG) prevents chronic kidney disease (CKD) and renal fibrosis based on preclinical evidence. The anti--oxidative stress properties of EGCG are exerted through its inhibition of mitochondrial dysfunction and its induction of antioxidant enzymes via activation of the Nrf2/HO-1 signaling pathway. For its anti-inflammation property, EGCG inhibits NF-κB signaling and inflammasome formation resulting in inhibition of the inflammatory cascade. Moreover, EGCG exhibits an anti-EMT property through various signaling pathways, including TGF-β1/Smad, β-catenin, and Nrf2 pathways, to prevent fibrotic transdifferentiation by the EMT process. Shaded boxes (in light orange) represent molecular events that occur in CKD, which can be inhibited or prevented by EGCG. ARE, antioxidant responsive element; Cul3, cullin-3; E2, E2 ubiquitin-conjugating enzyme; ECM, extracellular matrix; EMT, epithelial mesenchymal transition; GPx, glutathione peroxidase; HO-1, heme oxygenase 1; Keap1, Kelch-like ECH-associated protein 1; MDA, malondialdehyde; MPO, myeloperoxidase; NLRP3, nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3; NQO1, NAD(P)H:quinone oxidoreductase 1; Nrf2, nuclear factor erythroid 2-related factor 2; ROS, reactive oxygen species; SOD, superoxide dismutase; TGF-β1, transforming growth factor-β1; Ub, ubiquitin; ZO-1, zonula occludens-1; α-SMA, α-smooth muscle actin; 8-OHdG, 8-hydroxy-2\'-deoxyguanosine.](nzz101fig1){#fig1}

Challenges and Concerns for Clinical Use of EGCG {#sec4}
================================================

The health-promoting effects of EGCG involve many cellular and molecular mechanisms that remain poorly understood. Based on recent preclinical evidence, the Keap1-Nrf2 system has gained considerable attention as the therapeutic target to prevent progression of CKD because of its main function to protect cells from oxidative stress and inflammation ([@bib32], [@bib37]). Nrf2 activators or Keap1 inhibitors have been extensively investigated in many kidney disease models and some have already entered into clinical trials ([@bib74]). A phase 2/3 clinical trial (CARDINAL study) of an Nrf2 activator, bardoxolone methyl (also known as CDDO-methyl ester), in CKD patients is in progress ([@bib74]). Bardoxolone methyl is classified as an electrophilic Nrf2 activator, which can alter the Keap1--Cul3 interaction by direct complexing with Cys151 residing at the BTB (broad complex, tramtrack, and bric-a-brac) domain of Keap1 protein, resulting in an inability of Keap1--Cul3 to target Nrf2 for proteasomal degradation ([@bib33], [@bib75]). A covalent modification of thiol groups in Keap1 is thus crucial for regulation of Nrf2 signaling.

It has been demonstrated that EGCG can interact with specific residues of Keap1. In a rat model of fluoride-induced oxidative stress in lungs, EGCG has been shown to be docked in Keap1, forming interaction bonds with Gly343, Thr595, Leu578, and Asp579 ([@bib76]). Another molecular docking analysis has revealed that EGCG can directly interact with Ser508, Ser555, Ser602, Tyr525, Tyr572, Gln530, and Arg483 inside Keap1 through hydrogen bonding ([@bib42]). These interacting residues fall into P1, P3, and P4 subpockets within the kelch domain of Keap1, where interaction with ETGE and DLG motifs of Nrf2 takes place ([@bib77]). Therefore, it is possible that EGCG can disrupt the Keap1--Nrf2 interaction and thereby activate Nrf2 signaling through this molecular docking. Alternatively, EGCG probably induces Nrf2 activation via Keap1-independent mechanisms ([@bib34], [@bib80]), for example, transcription regulation (via microRNAs), posttranslational modification (phosphorylation, sumoylation, acetylation, methylation, etc.), and epigenetic factors, that cannot be ruled out and deserve further investigations in CKD models. This sheds light onto the potential use of EGCG or its derivatives as Nrf2 activators for preventing renal damage and progression of CKD. Nonetheless, because a relation between Nrf2 signaling and disease pathology is sophisticated and context-dependent, it is imperative to interpret and evaluate the information cautiously.

Although the Nrf2-based therapy has proven to be beneficial, another interesting approach is the mitochondria-targeting therapy. It is conceived that mitochondrial bioenergetics stress, increasing mitochondrial fission, and ROS overproduction in adaptation to nephron loss contribute to the CKD progression ([@bib19]). These alterations are well documented in the chronic stage of DN ([@bib81]). Maintaining mitochondrial homeostasis in terms of its dynamics and bioenergetics could offer beneficial effects over downstream events like inflammation and fibrogenesis ([@bib14]). A pharmacological strategy to improve mitochondrial dysfunction has been evaluated in animal models of both AKI and CKD ([@bib84]). Based on their disparate modes of action, such compounds are classified as cardiolipin-targeting peptides, mitochondria-targeting antioxidants, mitochondria-homing agents, mitochondrial biogenesis-stimulating agents, and fatty acid oxidation-stimulating agents ([@bib84]). Among these, Szeto--Schiller peptide (SS-31, also known as elamipretide) targeting cardiolipin has been tested in a phase 2a trial, with positive results showing that this compound could reduce postprocedural hypoxia, increase renal blood flow, and improve kidney function in patients with atherosclerotic renal artery stenosis ([@bib85]). Although the mitochondria-targeting antioxidants might help to preserve or improve mitochondrial function in CKD, only MitoQ has been entered into a phase 4 clinical trial (NCT02364648) of stages 3--5 CKD patients.

Interestingly, EGCG is also known as a mitochondria-targeting agent because of its well-documented roles in regulating mitochondrial biogenesis, bioenergetics, and mitochondria-dependent apoptosis ([@bib86]). For example, EGCG can increase mRNA expression level of PPAR-γ coactivator-1α (PGC-1α), a master regulator of mitochondrial biogenesis, in HepG2 cells and can differentiate 3T3-L1 adipocytes by enhancing the activity of PGC-1α promoter ([@bib87]). In a model of Down syndrome (DS), EGCG has been demonstrated to rescue oxidative phosphorylation and promote mitochondrial biogenesis in DS-phenotypically characterized fetal skin fibroblasts via cAMP/protein kinase A (PKA)- and SIRT1-dependent pathways ([@bib88]). Similar results were obtained when EGCG or resveratrol (another natural polyphenol) were tested in neural progenitor cells from a DS mouse model ([@bib90]). However, there are few experimental studies to support the protective effect of EGCG on renal mitochondria. Interestingly, a recent study has unveiled that a structurally modified EGCG prodrug (peracetylated EGCG, or AcEGCG), also known as 4″-*O*-alkyl AcEGCG derivative, can increase mitochondrial mass and mitochondrial DNA content and markedly enhance mitochondrial biogenesis ([@bib92]). As an enhancer of mitochondrial biogenesis, 4″-*O*-alkyl AcEGCG could enhance expression of many regulators for mitochondrial function (i.e., PGC-1α, phospho-5\' adenosine monophosphate-activated protein kinase (p-AMPK), SIRT1, estrogen-related receptor-α, nuclear respiratory factor 1, nuclear respiratory factor 2, and mitochondrial transcription factor A) ([@bib92]). Additionally, it could increase the NAD^+^/NADH ratio, cytochrome *c* concentration, ATP synthesis, and oxygen consumption in Hepa1-6 cells ([@bib92]). These findings underscore that an in-depth knowledge of compound structures and mitochondrial activities in combination with further development of powerful tools that can directly assess mitochondrial function is necessary for mitochondria-targeting pharmacotherapy in CKD.

Nonetheless, there is a big gap before EGCG is implemented in clinical use. Because of the low stability, poor absorption, and low bioavailability of EGCG ([@bib93], [@bib94]), clinical trials are quite sophisticated and translation of preclinical findings to clinical practice is currently handicapped. Recently, nanotechnology-based delivery systems, including metal-based and organic-based nanoparticles, have been applied to enhance EGCG bioavailability to overcome these difficulties ([@bib95], [@bib96]). A recent study in rats with nephrotic syndrome has shown improved bioavailability of EGCG when using EGCG-polymeric nanoparticles compared with free EGCG powder, resulting in improved renal function, reduced renal damage, and reduced proteinuria ([@bib93]). Although most of the preclinical studies using EGCG-loaded nanoparticles have provided promising results, there were some inconsistencies in terms of nanoparticle size, cytotoxicity effects at high doses, and pharmacokinetics. Furthermore, it is imperative to understand the pharmacokinetic interaction between EGCG and other drugs when EGCG is used as an adjuvant. However, such information is currently limited, especially at the level of the clinical trial ([@bib97], [@bib98]).

Unlike the progress made for clinical trials of EGCG in various cancers, there is currently no clinical study to demonstrate a renoprotective role of EGCG or green tea in CKD in humans. Besides the poor bioavailability of EGCG, the complexity of CKD in terms of extremely varied etiologies and natural history also contributes to this hurdle. Moreover, the pan-specific bioactivity of EGCG is also a concern ([**Figure 2**](#fig2){ref-type="fig"}). According to a substructure-based drug screening tool, EGCG is defined as one of the Pan-Assay INterference compoundS (PAINS) ([@bib99]). EGCG contains a PAINS motif, catechol, which frequently triggers signals in various bioassays by different mechanisms ([@bib100]). For example, catechol can undergo redox cycling, which causes formation of reactive chelators or orthoquinones that subsequently modify proteins, nucleic acids, or lipids ([Figure 2](#fig2){ref-type="fig"}). Such a property might also contribute to its cytotoxicity and affect its therapeutic efficacy ([@bib100]). However, care must be taken in interpreting the PAINS alerts because the existence of a PAINS substructure does not always convey PAINS behavior in a compound, and some FDA-approved drugs and dark chemical matters (compounds that have been tested in 100 or more assays but have never shown any substantial biological activity) contain the PAINS motif in their structures ([@bib101]).

![Potential pan-reactivity of epigallocatechin-3-gallate (EGCG). EGCG is one of the Pan-Assay INterference compoundS (PAINS) and contains a PAINS motif, catechol, that frequently triggers signals in various bioassays by different mechanisms. For example, catechol can undergo redox cycling that causes formation of reactive chelators or orthoquinones, which subsequently modify proteins, nucleic acids, or lipids.](nzz101fig2){#fig2}

In conclusion, although clinical research of EGCG in CKD is still immature, it is likely that EGCG might serve as a potential medication or adjuvant therapy for targeting many signaling pathways involved in CKD progression, including oxidative stress, inflammatory response, and energy sensing through mitochondria. Nonetheless, for safety, more efforts should be put into investigating specific targets of EGCG to minimize off-target effects and to better understand its mechanisms of action against CKD. More importantly, the clinical trials should be performed to precisely address whether EGCG is really beneficial for prevention of CKD and, if so, to what extent. Finally, connecting multiple pathways regulated by EGCG coupled with recent advances in drug delivery systems might accelerate the whole process to achieve the ultimate goal of effective prevention of CKD.
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